Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07130695 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Oct 31, 2027 to Oct 31, 2028
    • Study completion date: Oct 31, 2029 to Oct 31, 2030
    • Start date changed from estimate of Feb 1, 2026 to Feb 2, 2026
    • Site details revised
  2. Start date: Oct 31, 2025 to Feb 1, 2026v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Treatment with olutasidenib for isocitrate dehydrogenase 1 (IDH1) mutant acute myeloid leukemia (AML) after completion of traditional intensive induction/consolidation is likely to be safe, tolerable, and may provide clinical benefit in terms of maintenance of remission and perhaps improvement in survival.
Trial Details
NCT Number NCT07130695
Lead Sponsor Virginia Commonwealth University
Collaborators: Rigel Pharmaceuticals
Conditions
(from sponsor)		 Acute Myeloid Leukemia
Related terms Leukemia, Myeloid, Acute
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov